Wells Fargo downgraded Glaukos (GKOS) to Equal Weight from Overweight with a price target of $86, down from $160.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Positive Buy Rating for Glaukos Amid Strong iDose Performance and Awaited FDA Decision
- Glaukos’s Promising Outlook: Buy Rating Amid Strong Sales and Strategic Growth Opportunities
- Glaukos Corp. Reports Strong Q1 2025 Growth
- Closing Bell Movers: Microsoft and Meta rally after earnings
- Glaukos Reports Record Q1 2025 Net Sales Growth